Home / Business and Economy / Wall Street Bullish on Legend Biotech's Promising Future
Wall Street Bullish on Legend Biotech's Promising Future
23 Aug
Summary
- RBC Capital raises Legend Biotech's price target to $77
- Q2 beat suggests strong demand and successful manufacturing for Carvykti
- Anticipates growth in the US and additional acceleration ex-US
According to the latest analysis, Legend Biotech Corporation (NASDAQ:LEGN) is emerging as one of the most promising future stocks on Wall Street. On August 12, 2025, RBC Capital raised the firm's price target on Legend Biotech to $77 from $75, while maintaining an Outperform rating on the shares.
The analyst noted that Legend Biotech's strong Q2 2025 performance suggests continuing robust demand and successful manufacturing for its lead product, Carvykti. This supports the company's sustainable growth trajectory, with additional acceleration anticipated in markets outside the US.
Legend Biotech is a clinical-stage biopharmaceutical company that develops, discovers, manufactures, and commercializes novel therapies for oncology and other indications. The firm operates in the US, China, and other geographical segments, leveraging an elaborate range of advanced cell therapy technology platforms.
Looking ahead, the analyst sees several tailwinds for Legend Biotech, including the potential pull-through of 5-year overall survival (OS) data for Carvykti. This positive outlook underscores the company's promising future as it continues to advance its pipeline and expand its global footprint.
